Identification of 2-(4-pyridyl)thienopyridinones as GSK-3β inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 16, 2011, Pages 4823-4827

  Gentile, Gabriella ^a   Bernasconi, Giovanni ^a   Pozzan, Alfonso ^a   Merlo, Giancarlo ^a   Marzorati, Paola ^a   Bamborough, Paul ^b   Bax, Benjamin ^b   Bridges, Angela ^b   Brough, Caroline ^b   Carter, Paul ^b   Cutler, Geoffrey ^b   Neu, Margarete ^b   Takada, Mia ^b  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Glycogen synthase kinase 3 (GSK 3); GSK 3 inhibitors; Lead optimization

Indexed keywords

2 (4 PYRIDYL)THIENOPYRIDINONE DERIVATIVE; BORONIC ACID DERIVATIVE; CARBOXYLIC ACID; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; CYCLIN DEPENDENT KINASE 2; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL ACTIVITY; DEGENERATIVE DISEASE; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; X RAY CRYSTALLOGRAPHY;

CELL LINE; CENTRAL NERVOUS SYSTEM; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PERMEABILITY; PROTEIN KINASE INHIBITORS; PYRIDONES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 79960915206     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.06.050     Document Type: Article

References (17)

1. P. Cohen, and S. Frame Nat. Rev. Mol. Cell. Biol. 2 2001 769
2. S.E. Nikoulina, T.P. Ciararli, S. Mudaliar, L. Carter, K. Jonson, and R.R. Henry Diabetes 51 2002 2190
3. E. Planel, X. Sun, and A. Takashima Drug Dev. Res. 56 2002 491
4. C.J. Phiel, and P.S. Klein Annu. Rev. Pharmacol. Toxicol. 41 2001 789
5. P.S. Klein, and D.A. Melton Proc. Natl. Acad. Sci. U.S.A. 93 1996 8455
6. M. Aoki, M. Iwamoto-Sugai, I. Sugiura, C. Sasaki, T. Hasegawa, C. Okumura, S. Sugio, T. Kohono, and T. Matsuzaki Acta Crystallogr. D56 2000 1464
7. B. Bax, P.S. Carter, C. Lewis, A.R. Guy, A. Bridges, R. Tanner, G. Pettman, C. Mannix, A.A. Culbert, M.J.B. Brown, D.G. Smith, and A.D. Reith Structure (London) 9 2001 1143
8. J.A. Bertrand, S. Thieffine, A. Vulpetti, C. Cristiani, B. Valsasina, S. Knapp, H.M. Kalisz, and M. Flocco J. Mol. Biol. 333 2003 393
9. H. Pajouhesh, and G.R. Lenz NeuroRx. 2 2005 541
10. Topological polar surface area (tPSA) was calculated by the method of P. Ertl, B. Rohde, and P. Selzer J. Med. Chem. 43 2000 3714
11. D.E. Clark Future Med. Chem. 3 2011 469
12. Available Chemical Directory (ACD) database, 2009, www.symix.com.
13. The Daylight toolkit is available from Daylight, 2009, www.daylight.com.
14. Calculated MCDK2 permeability and predicted Brain Tissue Binding models are in-house models derived from internal GSK data. tPSA was computed using the Ertl methods (a) Ertl, E.; Rohde, B.; Selzer, P. J. Med. Chem. 2000, 473, 3714
15. GOLD v. 3.2 (2007) is a docking program available from CCDC, http://www.ccdc.cam.ac.uk.
16. M.L. Verdonk, G. Chessari, J.C. Cole, M.J. Hartshorn, C.W. Murray, J.W.M. Nissink, R.D. Taylor, and R. Taylor J. Med. Chem. 48 2005 6504
17. k-Means clustering was performed using the module available within Spotfire Decision Site 8.2.1 (http:// spotfire.tibco.com/). The Euclidean distance was used as similarity measure and the selection of the 27 molecules was based on maximizing the number of clusters represented in the smaller set.